



PATENT
1110-0279P

IN THE U.S. PATENT AND TRADEMARK OFFICE

RECEIVED

JUL 19 2002

TECH CENTER 1600/2900

Applicant: Yoshiyuki UENO Conf.: 3959
Appl. No.: 09/700,338 Group: 1648
Filed: November 14, 2000 Examiner: U. WINKLER
For: PREVENTIVES/REMEDIES FOR HEPATIC
CIRRHOSIS

LARGE ENTITY TRANSMITTAL FORM

Assistant Commissioner for Patents
Washington, DC 20231

July 18, 2002

Sir:

Transmitted herewith is a Reply to Restriction/Election Requirement in the above-identified application.

- ☐ The enclosed document is being transmitted via the Certificate of Mailing provisions of 37 C.F.R. § 1.8.
- ☐ Petition for _____ () month(s) extension of time pursuant to 37 C.F.R. §§ 1.17 and 1.136(a). \$0.00 for the extension of time.
- ☒ No fee is required.
- ☐ A check in the amount of \$0.00 is enclosed.
- ☐ Please charge Deposit Account No. 02-2448 in the amount of \$0.00. A triplicate copy of this sheet is attached.

Appl. No. 09/700,338

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. §§1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP


By *ma armstrong*
Gerald M. Murphy, Jr., #28,977

MaryAnne Armstrong, PhD., #40,069

GMM/MAA/csm
1110-0279P

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

(Rev. 09/27/01)



Elec./Omdt. #6
PATENT 7/22/02
1110-0279P

IN THE U.S. PATENT AND TRADEMARK OFFICE

RECEIVED

Applicant: Yoshiyuki UENO Conf.: 3959
Appl. No.: 09/700,338 Group: 1648
Filed: November 14, 2000 Examiner: U. Winkler
For: PREVENTIVES/REMEDIES FOR HEPATIC
CIRRHOSIS

JUL 19 2002

TECH CENTER 1600/2900

REPLY TO RESTRICTION REQUIREMENT

Assistant Commissioner for Patents
Washington, DC 20231

July 18, 2002

Sir:

In reply to the Restriction Requirement dated June 18, 2002, the following amendments and remarks are respectfully submitted in connection with the above-identified application.

IN THE SPECIFICATION:

Please replace the paragraph beginning on page 20, line 7, with the following rewritten paragraph:

--The anti-Fas ligand antibody and the anti-Fas antibody used in the present invention may be prepared by known process, for example, by the process described in International Patent Application Publication No. WO 95/13293 and International Patent

B1